Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved a revenue of 1.766 billion yuan in 2024, representing a year-on-year growth of 29.26%, and a net profit of 106.4 million yuan, up 94.58% year-on-year [7] - The self-owned brand "Zhenjia" has shown significant growth, with a revenue of 501 million yuan in 2024, a year-on-year increase of 90.28%, contributing to 28.37% of the company's total revenue [7] - The company has successfully launched the health product line "Feicui," which has rapidly gained traction, ranking high in various e-commerce platforms [7] - The brand management business has also demonstrated strong growth, with a revenue of 501 million yuan in 2024, up 212.24% year-on-year [7] - The company has adjusted its net profit forecasts for 2025-2026 upwards due to better-than-expected growth in self-owned brands, with 2025 net profit now projected at 190 million yuan [7] Financial Summary - Total revenue is projected to reach 2.685 billion yuan in 2025, with a year-on-year growth of 52.06% [1] - The net profit for 2025 is estimated at 189.82 million yuan, reflecting a year-on-year increase of 79.70% [1] - The earnings per share (EPS) is expected to be 1.16 yuan in 2025, with a price-to-earnings (P/E) ratio of 43.13 [1] - The gross margin is expected to improve to 52.62% in 2025, up from 44.57% in 2024 [8] - The company's total assets are projected to be 1.511 billion yuan in 2025, with a debt-to-asset ratio of 28.34% [8]